



=> d l1; d l4; d his; log y
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.
L4 HAS NO ANSWERS
L4 STR



Structure attributes must be viewed using STN Express query preparation.

(FILE 'HOME' ENTERED AT 19:50:42 ON 15 MAY 2003)

FILE 'REGISTRY' ENTERED AT 19:50:48 ON 15 MAY 2003

L1 STRUCTURE UPLOADED
L2 9 S L1
L3 1179 S L1 FUL
L4 STRUCTURE UPLOADED
L5 6 S L4 SAM SUB=L3
L6 201 S L4 FUL SUB=L3
L7 978 S L3 NOT L6

FILE 'CAPLUS' ENTERED AT 19:52:12 ON 15 MAY 2003

L8 85 S L7


COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	388.48	572.14
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-55.34	-55.34

STN INTERNATIONAL LOGOFF AT 19:56:18 ON 15 MAY 2003

L8 ANSWER 21 OF 85 CAPLUS COPYRIGHT 2003 ACS
 AN 2000:227868 CAPLUS
 DN 132:262407
 TI Biological reagents and methods for determining the mechanism in the generation of .beta.-amyloid peptide
 IN Audia, James E.; Hyslop, Paul A.; Nissen, Jeffrey S.; Thompson, Richard C.; Tung, Jay S.; Tanner, Laura I.
 PA Elan Pharmaceuticals, Inc., USA; Eli Lilly and Company
 SO PCT Int. Appl., 86 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000019210	A2	20000406	WO 1999-US22684	19990929
	WO 2000019210	A3	20010118		
	W:		AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
	AU 9962780	A1	20000417	AU 1999-62780	19990929
	EP 1131634	A2	20010912	EP 1999-950039	19990929
	R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO		
	US 6486350	B1	20021126	US 1999-408283	19990929
	US 2003069445	A1	20030410	US 2002-217459	20020814
PRAI	US 1998-160082P	P	19980930		
	US 1999-408283	A3	19990929		
	WO 1999-US22684	W	19990929		
OS	MARPAT 132:262407				
AB	Biol. reagents are described which comprise compds. that inhibit .beta.-amyloid peptide release and/or its synthesis. These compds. have utility in detg. the cellular mechanism involved in the generation of .beta.-amyloid peptide. The synthesis of these compds. are described extensively.				
IT	209984-57-6P RL: ARU (Analytical role, unclassified); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); SPN (Synthetic preparation); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses) (synthesis of biol. reagents and methods for detg. mechanism in generation of .beta.-amyloid peptide)				
RN	209984-57-6 CAPLUS				
CN	Benzeneacetamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro-.alpha.-hydroxy-, (.alpha.S)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry. Rotation (-).



IT 209984-58-7P 209984-68-9P

RL: ARU (Analytical role, unclassified); BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified);

SPN

(Synthetic preparation); ANST (Analytical study); BIOL (Biological study);


PREP (Preparation); PROC (Process); USES (Uses)

(synthesis of biol. reagents and methods for detg. mechanism in generation of .beta.-amyloid peptide)

RN 209984-58-7 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro-α-hydroxy-, (α.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 209984-68-9 CAPLUS

CN Butanamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-2-hydroxy-3-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 209984-35-0 253324-50-4


RL: RCT (Reactant); RACT (Reactant or reagent)

(synthesis of biol. reagents and methods for detg. mechanism in generation of .beta.-amyloid peptide)

RN 209984-35-0 CAPLUS

CN Propanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 253324-50-4 CAPLUS

CN Propanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 26 OF 85 CAPLUS COPYRIGHT 2003 ACS

AN 1999:819352 CAPLUS

DN 132:64533

TI Preparation of cyclic amino acid compounds for inhibiting .beta.-amyloid peptide release and/or its synthesis

IN Audia, James E.; Thompson, Richard C.; Wilkie, Stephen C.; Britton, Thomas

C.; Porter, Warren J.; Huffman, George W.; Latimer, Lee H.

PA Elan Pharmaceuticals, Inc., USA; Eli Lilly & Company

SO PCT Int. Appl., 271 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9967220	A1	19991229	WO 1999-US14007	19990621
	W:				
	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2325388	AA	19991229	CA 1999-2325388	19990621
	AU 9952047	A1	20000110	AU 1999-52047	19990621
	EP 1089981	A1	20010411	EP 1999-937164	19990621
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002518482	T2	20020625	JP 2000-555874	19990621
	US 6509331	B1	20030121	US 1999-337484	19990621
PRAI	US 1998-102728	A2	19980622		
	US 1998-155265P	P	19980622		
	WO 1999-US14007	W	19990621		
OS	MARPAT 132:64533				
AB	Compds. R1(Z)mNH(Y)nW [W is a fused ring system, e.g., benzo- or dibenzoazepinones or -diazepinones; Y = CHR2CONH or (CHR2')aNH, where R2 =				
	(un)substituted alkyl, alkenyl, or alkynyl, cycloalkyl, aryl, heteroaryl,				
	heterocyclyl, R2' = H or R2; R1 = (un)substituted alkyl, alkenyl, alkynyl,				
	cycloalkyl, or cycloalkenyl, aryl, heteroaryl, heterocyclyl, Z =				
	-T-CX'X''CO, where T is selected from the group consisting of a bond covalently linking R1 to -CX'X''-, oxygen, sulfur and -NR6 (R6 = H,				
	acyl,				
	alkyl, aryl, heteroaryl), X' is H, OH, F, X'' is H, OH, F or X' and X''				
	together form an oxo group; m = 0 or 1; n = 1 or 2] were prep'd. for				
	inhibition of .beta.-amyloid peptide release and/or its synthesis.				
Thus,	1-(L-alaninylamino)-4,5,6,7-tetrahydro-3,7-methano-3H-3-benzazonin-				
	2(1H)-				
	one was prep'd. via coupling of N-tert-butoxycarbonyl-L-alanine with				
	1-amino-4,5,6,7-tetrahydro-3,7-methano-3H-3-benzazonin-2(1H)-one.				
	Compds.				

of the invention inhibit .beta.-amyloid peptide prodn. by at least 30% as

compared to the control when employed at 10 .mu.g/mL.

IT 209994-99-0P 228877-30-3P 228877-32-5P

228877-95-0P 229021-48-1P 253185-47-6P

253185-49-8P 253185-51-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. of cyclic amino acid compds. for inhibiting .beta.-amyloid peptide release)

RN 209994-99-0 CAPLUS

CN Propanamide, 2-amino-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-

yl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 228877-30-3 CAPLUS

CN Butanamide, 2-amino-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-

yl)-3-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 228877-32-5 CAPLUS

CN Butanamide, 2-amino-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-

yl)-3,3-dimethyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-95-0 CAPLUS

CN Propanamide, 2-amino-N-(5,6,8,9-tetrahydro-8-oxo-4H-benzo[d]pyrido[3,2,1-jk][1]benzazepin-9-yl)-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 229021-48-1 CAPLUS

CN Propanamide, 2-amino-N-(1,2,4,5,6,7-hexahydro-2-oxo-3,7-methano-3H-3-benzazonin-1-yl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253185-47-6 CAPLUS

CN Propanamide, 2-amino-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-, (2S)- (9CI) (CA INDEX NAME)

yl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253185-49-8 CAPLUS

CN Butanamide, 2-amino-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-

yl)-3-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253185-51-2 CAPLUS

CN Butanamide, 2-amino-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-

yl)-3,3-dimethyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 228877-28-9P 228877-29-0P 228877-31-4P

228877-58-5P 229021-47-0P 253185-46-5P
253185-48-7P 253185-50-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);

RACT

(Reactant or reagent)

(prep. of cyclic amino acid compds. for inhibiting .beta.-amyloid
peptide release)

RN 228877-28-9 CAPLUS


CN Carbamic acid, [(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-
dibenz[b,d]azepin-7-

yl)amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA

INDEX

NAME)

Absolute stereochemistry.



RN 228877-29-0 CAPLUS


CN Carbamic acid, [(1S)-1-[[(6,7-dihydro-5-methyl-6-oxo-5H-
dibenz[b,d]azepin-

7-yl)amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI)

(CA

INDEX NAME)

Absolute stereochemistry.




RN 228877-31-4 CAPLUS

CN Carbamic acid, [(1S)-1-[[(6,7-dihydro-5-methyl-6-oxo-5H-


dibenz[b,d]azepin-
 7-yl)amino]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 228877-58-5 CAPLUS
 CN Carbamic acid, [(1S)-1-methyl-2-oxo-2-[(5,6,8,9-tetrahydro-8-oxo-4H-benzo[d]pyrido[3,2,1-jk][1]benzazepin-9-yl)amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 229021-47-0 CAPLUS
 CN Carbamic acid, [(1S)-2-[(1,2,4,5,6,7-hexahydro-2-oxo-3,7-methano-3H-3-benzazonin-1-yl)amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253185-46-5 CAPLUS
 CN Carbamic acid, [(1R)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA
 INDEX
 NAME)

Absolute stereochemistry.



RN 253185-48-7 CAPLUS
 CN Carbamic acid, [(1R)-1-[[[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI)
 (CA
 INDEX NAME)


Absolute stereochemistry.



RN 253185-50-1 CAPLUS

CN Carbamic acid, [(1R)-1-[[[6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 27 OF 85 CAPLUS COPYRIGHT 2003 ACS

AN 1999:819351 CAPLUS

DN 132:64532

TI Preparation of cyclic amino acid compounds for inhibiting .beta.-amyloid peptide release and/or its synthesis

IN Audia, James E.; Porter, Warren J.; Thompson, Richard C.; Wilkie, Stephen

C.; Stack, Douglas R.; Shi, Qing

PA Elan Pharmaceuticals, Inc., USA; Eli Lilly & Company

SO PCT Int. Appl., 287 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9967219	A1	19991229	WO 1999-US14096	19990622
	W:				
	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2324474	AA	19991229	CA 1999-2324474	19990622
	AU 9947079	A1	20000110	AU 1999-47079	19990622
	EP 1089977	A1	20010411	EP 1999-930566	19990622
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002518481	T2	20020625	JP 2000-555873	19990622
	US 6552013	B1	20030422	US 1999-338121	19990622
PRAI	US 1998-102507	A2	19980622		
	US 1998-162757	A2	19980930		
	US 1998-160067P	P	19980622		
	US 1998-150704P	P	19980930		
	WO 1999-US14096	W	19990622		

OS MARPAT 132:64532

AB Comps. R1ZNH(Y)nW [W is a fused ring system, e.g., benzo- or dibenzoazepinones or -diazepinones; Y = CHR2CONH, where R2 = (un)substituted alkyl, alkenyl, or alkynyl, cycloalkyl, aryl,

heteroaryl,

heterocyclyl; R1 = (un)substituted alkyl, alkenyl, cycloalkyl, or cycloalkenyl, aryl, heteroaryl, heterocyclyl; Z is represented by -T-CX'X''V- where T is selected from the group consisting of a bond covalently linking R1 to -CX'X''-, oxygen, sulfur and -NR6 (R6 = H,

acyl,

alkyl, aryl, heteroaryl), X' is H, OH, F, X'' is H, OH, F or X' and X'' together form an oxo group, V is alkylene or substituted alkylene or R1 and Z together form aryl or (un)substituted cycloalkyl, cycloalkenyl, or heterocyclyl; n = 1 or 2] were prepd. for inhibition of .beta.-amyloid peptide release and/or its synthesis. Thus, 5-(S)-[N'-(2-(3,5-difluorophenyl)ethyl)-L-alaninyl]amino-7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one was prepd. by reductive alkylation of 5-(S)-(L-alaninyl)amino-7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one hydrochloride with 3,5-difluorophenylacetaldehyde using sodium

cyanoborohydride. Compds. of the invention inhibit .beta.-amyloid peptide prodn. by at least 30% as compared to the control when employed at 10 .mu.g/mL.


IT 253161-81-8P 253161-91-0P 253161-92-1P
253161-93-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of cyclic amino acid compds. for inhibiting .beta.-amyloid peptide release)

RN 253161-81-8 CAPLUS

CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-
2-[[[(1R,2S)-1,2,3,4-tetrahydro-1-hydroxy-2-naphthalenyl]amino]-, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253161-91-0 CAPLUS

CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-
2-[[[(1S,2S)-1,2,3,4-tetrahydro-1-hydroxy-2-naphthalenyl]amino]-, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253161-92-1 CAPLUS


CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-
2-[[[(1S,2R)-1,2,3,4-tetrahydro-1-hydroxy-2-naphthalenyl]amino]-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 253161-93-2 CAPLUS
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-
 2-[[[(1R,2R)-1,2,3,4-tetrahydro-1-hydroxy-2-naphthalenyl]amino]-, (2S)-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 209984-35-0P 209984-36-1P 209984-39-4P
 209984-40-7P 229021-48-1P 253135-42-1P
 253136-05-9P 253161-60-3P 253161-61-4P
 253161-62-5P 253161-63-6P 253161-64-7P
 253161-65-8P 253161-66-9P 253161-67-0P
 253161-68-1P 253161-69-2P 253161-70-5P
 253161-71-6P 253161-72-7P 253161-73-8P
 253161-74-9P 253161-76-1P 253161-77-2P
 253161-78-3P 253161-82-9P 253161-83-0P
 253161-84-1P 253161-85-2P 253161-86-3P
 253161-95-4P

RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic
 use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of cyclic amino acid compds. for inhibiting .beta.-amyloid
 peptide release)
 RN 209984-35-0 CAPLUS
 CN Propanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-
 dibenz[b,d]azepin-7-yl]-, monohydrochloride, (2S)- (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.



● HCl

RN 209984-36-1 CAPLUS
 CN Propanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209984-39-4 CAPLUS
 CN Butanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 209984-40-7 CAPLUS

CN Butanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 229021-48-1 CAPLUS

CN Propanamide, 2-amino-N-(1,2,4,5,6,7-hexahydro-2-oxo-3,7-methano-3H-benzazonin-1-yl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253135-42-1 CAPLUS

CN Propanamide, 2-amino-N-[6,7-dihydro-5-(2-methylpropyl)-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

NAME)

Absolute stereochemistry.




● HCl

RN 253136-05-9 CAPLUS

CN Propanamide, 2-amino-N-(2,3,4,5-tetrahydro-1-methyl-2-oxo-5-phenyl-1H-1-benzazepin-3-yl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253161-60-3 CAPLUS

CN Propanamide, 2-[[2-(3,5-difluorophenyl)ethyl]amino]-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-61-4 CAPLUS

CN Propanamide, 2-[[[(2R)-2-(3,5-difluorophenyl)-2-hydroxyethyl]amino]-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2S)- (9CI) (CA INDEX NAME)


6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-62-5 CAPLUS
 CN Propanamide, 2-[[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethyl]amino]-N-
 [(7S)-
 6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-63-6 CAPLUS
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-
 2-[[2-hydroxy-3-(1-methylethoxy)propyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-64-7 CAPLUS
CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-
2-[(2-hydroxybutyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-65-8 CAPLUS
CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-
2-[(2,3-dihydroxypropyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 253161-66-9 CAPLUS
CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-
2-[[2-hydroxy-3-(4-morpholinyl)propyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-67-0 CAPLUS

CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-

2-[(2-hydroxytetradecyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-68-1 CAPLUS

CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-

2-[(2-hydroxyoctyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-69-2 CAPLUS

CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-


2-[[2-hydroxy-2-(3,4,5-trifluorophenyl)ethyl]amino]-, (2S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 253161-70-5 CAPLUS
CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-
2-[[2-((2S)-2-hydroxy-2-(3,4,5-trifluorophenyl)ethyl)amino]-, (2S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 253161-71-6 CAPLUS
CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-
2-[[2-((2R)-2-hydroxy-2-[4-(trifluoromethyl)phenyl]ethyl)amino]-, (2S)-
(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 253161-72-7 CAPLUS
CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-
2-[[2-((2S)-2-hydroxy-2-[4-(trifluoromethyl)phenyl]ethyl)amino]-, (2S)-

(CA INDEX NAME)

CN1C(=O)S2C(=N1)c3ccccc3C2NC(=O)S[C@H](C)NSC[C@H](O)Sc4ccc(C(F)(F)F)cc4

CN Propanamide, 2-[[(2R)-2-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxyethyl]amino]-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2S)- (9CI) (CA INDEX NAME)


CN Propanamide, 2-[[(2S)-2-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxyethyl]amino]-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2S)- (9CI) (CA INDEX NAME)

Chemical structure of compound 10: A benzothiazine derivative. The structure features a benzothiazine core with a methyl group on the nitrogen atom. The sulfur atom of the benzothiazine ring is linked via a dashed bond to the nitrogen of an amide group. This amide is connected to a chiral center (S) bonded to a methyl group and another sulfur atom. This second sulfur atom is linked to a chiral center (N) bonded to a hydrogen atom and a third sulfur atom. The third sulfur atom is bonded to a 3,5-bis(trifluoromethyl)phenyl group. The stereochemistry at the chiral centers is indicated by wedges and dashes.

CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-
2-[[[(2S)-3,3,3-trifluoro-2-hydroxypropyl]amino]-, (2S)- (9CI) (CA INDEX

NAME)

Absolute stereochemistry.




RN 253161-77-2 CAPLUS

CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-

2-[(3-methyl-2-oxobutyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-78-3 CAPLUS

CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-


2-[[(2S)-2-hydroxy-3-methylbutyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 253161-82-9 CAPLUS
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-
 2-[[[(2S)-1,2,3,4-tetrahydro-1-oxo-2-naphthalenyl]amino]-,
 monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 253161-83-0 CAPLUS
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-
 2-[[[(2R)-1,2,3,4-tetrahydro-1-oxo-2-naphthalenyl]amino]-,
 monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 253161-84-1 CAPLUS
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-

yl]-

2-[(1,2,3,4-tetrahydro-2-naphthalenyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-85-2 CAPLUS

CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-

2-[(2-hydroxycyclohexyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-86-3 CAPLUS

CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-

2-[(4-methylpentyl)amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253161-95-4 CAPLUS

CN L-Alaninamide, N-(4-methylpentyl)-L-valyl-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 209984-33-8P 209984-34-9P 209984-37-2P
 209984-38-3P 209984-41-8P 209984-42-9P
 209984-43-0P 209984-44-1P 228877-58-5P
 228877-95-0P 229021-47-0P 253135-43-2P
 253136-04-8P 253161-58-9P 253161-75-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);

RACT


(Reactant or reagent)

(prepn. of cyclic amino acid compds. for inhibiting .beta.-amyloid peptide release)

RN 209984-33-8 CAPLUS

CN Carbamic acid, [(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-34-9 CAPLUS


CN Carbamic acid, [(1S)-2-[[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209984-37-2 CAPLUS
 CN Carbamic acid, [(1S)-1-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl
 ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209984-38-3 CAPLUS
 CN Carbamic acid, [(1S)-1-[[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl
 ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-41-8 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-42-9 CAPLUS


CN Carbamic acid, [(1S)-1-[[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209984-43-0 CAPLUS
 CN Butanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3,3-dimethyl-, monohydrochloride, (2S)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209984-44-1 CAPLUS
 CN Butanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3,3-dimethyl-, monohydrochloride, (2S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 228877-58-5 CAPLUS

CN Carbamic acid, [(1S)-1-methyl-2-oxo-2-[(5,6,8,9-tetrahydro-8-oxo-4H-benzo[d]pyrido[3,2,1-jk][1]benzazepin-9-yl)amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-95-0 CAPLUS

CN Propanamide, 2-amino-N-(5,6,8,9-tetrahydro-8-oxo-4H-benzo[d]pyrido[3,2,1-jk][1]benzazepin-9-yl)-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 229021-47-0 CAPLUS

CN Carbamic acid, [(1S)-2-[(1,2,4,5,6,7-hexahydro-2-oxo-3,7-methano-3H-3-benzazonin-1-yl)amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253135-43-2 CAPLUS

CN Carbamic acid, [(1S)-2-[(6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-04-8 CAPLUS

CN Carbamic acid, [(1S)-1-methyl-2-oxo-2-[(2,3,4,5-tetrahydro-1-methyl-2-oxo-5-phenyl-1H-1-benzazepin-3-yl)amino]ethyl]-, 1,1-dimethylethyl ester

(9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 253161-58-9 CAPLUS

CN 5,7-Dioxa-10-aza-2-siladodecan-12-amide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2,2,11-trimethyl-8-(1-methylethyl)-, (8S,11S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253161-75-0 CAPLUS

CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-[[[(2R)-3,3,3-trifluoro-2-hydroxypropyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 28 OF 85 CAPLUS COPYRIGHT 2003 ACS
 AN 1999:819249 CAPLUS
 DN 132:64531
 TI Preparation of cyclic amino acid compounds for inhibiting .beta.-amyloid peptide release and/or its synthesis
 IN Audia, James E.; Dressman, Bruce A.; Shi, Qing
 PA Elan Pharmaceuticals, Inc., USA; Eli Lilly & Company
 SO PCT Int. Appl., 256 pp.

CODEN: PIXXD2

DT Patent
 LA English


FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9966934	A1	19991229	WO 1999-US14211	19990622
	W:				
	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2324475	AA	19991229	CA 1999-2324475	19990622
	AU 9947104	A1	20000110	AU 1999-47104	19990622
	EP 1093372	A1	20010425	EP 1999-930600	19990622
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002518451	T2	20020625	JP 2000-555620	19990622
PRAI	US 1998-102507	A2	19980622		
	US 1998-164451	A2	19980930		
	WO 1999-US14211	W	19990622		
OS	MARPAT 132:64531				
AB	Compds. R'R''NCHR1CONH(Y)nW and R':NC(:R1)CONH(Y)nW [W is a fused ring system, e.g., benzo- or dibenzazepinones or -diazepinones; Y = CHR2CONH, where R2 = (un)substituted alkyl, alkenyl, or alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl; R1 and R' form a nitrogen-contg. heterocycle; R'' = H, alkyl, substituted alkyl, aryl; n = 1 or 2] were prep'd. for inhibition of .beta.-amyloid peptide release and/or its synthesis.				
Thus,	5-(S)-[N'-(L-prolyl)-L-alaninyl]amino-7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one was prep'd. via coupling of N-(N'-tert-butoxycarbonyl-L-prolyl)-L-alanine with 5-(S)-amino-7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one. Compds. of the invention inhibit .beta.-amyloid peptide prodn. by at least 30% as compared to the control when employed at 10 .mu.g/mL.				
IT	209984-35-0P 209984-36-1P 209984-39-4P 209984-40-7P 209984-43-0P 209984-44-1P 229021-48-1P 253135-42-1P 253136-05-9P 253136-07-1P 253136-11-7P 253136-15-1P 253136-19-5P 253136-20-8P 253136-23-1P 253136-27-5P 253136-32-2P 253136-36-6P 253136-39-9P 253136-41-3P 253136-43-5P 253136-45-7P 253136-52-6P 253136-53-7P				

253136-61-7P 253136-65-1P 253136-66-2P
 253136-68-4P 253136-69-5P 253136-71-9P
 253136-74-2P 253136-75-3P 253136-76-4P
 253136-77-5P 253194-30-8P 253194-32-0P
 253194-34-2P

RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic
 use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of cyclic amino acid compds. for inhibiting .beta.-amyloid
 peptide release)
 RN 209984-35-0 CAPLUS
 CN Propanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-
 dibenz[b,d]azepin-7-yl]-, monohydrochloride, (2S)- (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.



● HCl

RN 209984-36-1 CAPLUS
 CN Propanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-
 dibenz[b,d]azepin-7-yl]-, monohydrochloride, (2S)- (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.



HCl

RN 209984-39-4 CAPLUS
 CN Butanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209984-40-7 CAPLUS
 CN Butanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209984-43-0 CAPLUS
 CN Butanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3,3-dimethyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209984-44-1 CAPLUS
 CN Butanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3,3-dimethyl-, monohydrochloride, (2S)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 229021-48-1 CAPLUS
 CN Propanamide, 2-amino-N-(1,2,4,5,6,7-hexahydro-2-oxo-3,7-methano-3H-3-benzazonin-1-yl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253135-42-1 CAPLUS
 CN Propanamide, 2-amino-N-[6,7-dihydro-5-(2-methylpropyl)-6-oxo-5H-

dibenz[b,d]azepin-7-yl]-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 253136-05-9 CAPLUS

CN Propanamide, 2-amino-N-(2,3,4,5-tetrahydro-1-methyl-2-oxo-5-phenyl-1H-1-benzazepin-3-yl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-07-1 CAPLUS

CN L-Alaninamide, L-prolyl-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-11-7 CAPLUS

CN 2-Piperidinecarboxamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-15-1 CAPLUS

CN 2-Piperidinecarboxamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-19-5 CAPLUS

CN 1-Isoquinolinecarboxamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]]-1,2,3,4-tetrahydro-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-20-8 CAPLUS


CN 1-Isoquinolinecarboxamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]]-1,2,3,4-tetrahydro-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-23-1 CAPLUS
 CN L-Alaninamide, (4S)-4-(3-methylbutyl)-L-prolyl-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-27-5 CAPLUS
 CN L-Alaninamide, (4R)-4-(3-methylbutyl)-L-prolyl-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 253136-32-2 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-2,3-dihydro-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-36-6 CAPLUS

CN 1H-Indole-2-carboxamide, N-[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-2,3-dihydro-, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-39-9 CAPLUS

CN L-Alaninamide, (4R)-4-hydroxy-L-prolyl-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-41-3 CAPLUS

CN L-Alaninamide, (4R)-4-hydroxy-L-prolyl-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-43-5 CAPLUS

CN 2-Quinolinecarboxamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-1,2,3,4-tetrahydro-, (2R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-45-7 CAPLUS

CN 2-Quinolinecarboxamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-1,2,3,4-tetrahydro-, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-52-6 CAPLUS

CN 1H-Indole-2-carboxamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-2,3-dihydro-3,3-dimethyl-, (2R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-53-7 CAPLUS

CN 1H-Indole-2-carboxamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-2,3-dihydro-3,3-dimethyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-61-7 CAPLUS

CN 1H-Indole-2-carboxamide, N-[(1S)-2-[[[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino)-1-methyl-2-oxoethyl]-2,3-dihydro-2-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-65-1 CAPLUS

CN 1H-Indole-2-carboxamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino)-1-methyl-2-oxoethyl]-2,3-dihydro-2-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-66-2 CAPLUS


CN 1H-Indole-2-carboxamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-68-4 CAPLUS

CN 1H-Indole-2-carboxamide, 2,3-dihydro-3,3-dimethyl-N-[(1S)-1-methyl-2-oxo-2-[[[(1S)-2,3,4,5-tetrahydro-3-methyl-2-oxo-1H-3-benzazepin-1-yl]amino]ethyl]-, (2R)- (9CI) (CA INDEX NAME)



RN 253136-69-5 CAPLUS

CN 1H-Indole-2-carboxamide, 2,3-dihydro-3,3-dimethyl-N-[(1S)-1-methyl-2-oxo-2-[[[(1S)-2,3,4,5-tetrahydro-3-methyl-2-oxo-1H-3-benzazepin-1-yl]amino]ethyl]-, (2S)- (9CI) (CA INDEX NAME)




RN 253136-71-9 CAPLUS

CN 2-Quinololinecarboxamide, 1,2,3,4-tetrahydro-N-[(1S)-1-methyl-2-oxo-2-[(1S)-2,3,4,5-tetrahydro-3-methyl-2-oxo-1H-3-benzazepin-1-yl]amino]ethyl]- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 253136-74-2 CAPLUS

CN 2-Quinololinecarboxamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-75-3 CAPLUS

CN 2-Piperidinecarboxamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-76-4 CAPLUS

CN 2-Quinolonecarboxamide, 1,2,3,4-tetrahydro-N-[(1S)-1-methyl-2-oxo-2-[[[(1S)-2,3,4,5-tetrahydro-3-methyl-2-oxo-1H-3-benzazepin-1-yl]amino]ethyl]-, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 253136-77-5 CAPLUS

CN 2-Quinolonecarboxamide, 1,2,3,4-tetrahydro-N-[(1S)-1-methyl-2-oxo-2-[[[(1S)-2,3,4,5-tetrahydro-3-methyl-2-oxo-1H-3-benzazepin-1-yl]amino]ethyl]-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 253194-30-8 CAPLUS

CN 1H-Indole-2-carboxamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]octahydro-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253194-32-0 CAPLUS

CN 2-Quinolinecarboxamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]decahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253194-34-2 CAPLUS

CN 2-Quinolinecarboxamide, N-[(1S)-2-[[[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino)-1-methyl-2-oxoethyl]decahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 253136-51-5 253136-72-0


RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of cyclic amino acid compds. for inhibiting .beta.-amyloid peptide release)

RN 253136-51-5 CAPLUS

CN 1H-Indole-1-carboxylic acid, 2-[[[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-2,3-dihydro-3,3-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-72-0 CAPLUS

CN Propanamide, 2-amino-N-[(1S)-2,3,4,5-tetrahydro-3-methyl-2-oxo-1H-3-benzazepin-1-yl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 209984-33-8P 209984-34-9P 209984-37-2P
209984-38-3P 209984-41-8P 209984-42-9P
228877-58-5P 228877-95-0P 229021-47-0P
253135-43-2P 253136-04-8P 253136-06-0P
253136-10-6P 253136-14-0P 253136-18-4P
253136-21-9P 253136-26-4P 253136-31-1P
253136-34-4P 253136-38-8P 253136-42-4P
253136-59-3P 253136-63-9P 253136-67-3P
253136-70-8P 253194-29-5P 253194-31-9P
253194-33-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);

RACT


(Reactant or reagent)

(prepn. of cyclic amino acid compds. for inhibiting .beta.-amyloid peptide release)

RN 209984-33-8 CAPLUS

CN Carbamic acid, [(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-34-9 CAPLUS

CN Carbamic acid, [(1S)-2-[[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-37-2 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-38-3 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-41-8 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-42-9 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-58-5 CAPLUS


CN Carbamic acid, [(1S)-1-methyl-2-oxo-2-[(5,6,8,9-tetrahydro-8-oxo-4H-benzo[d]pyrido[3,2,1-jk][1]benzazepin-9-yl)amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228877-95-0 CAPLUS
 CN Propanamide, 2-amino-N-(5,6,8,9-tetrahydro-8-oxo-4H-benzo[d]pyrido[3,2,1-jk][1]benzazepin-9-yl)-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 229021-47-0 CAPLUS
 CN Carbamic acid, [(1S)-2-[(1,2,4,5,6,7-hexahydro-2-oxo-3,7-methano-3H-3-benzazonin-1-yl)amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253135-43-2 CAPLUS
 CN Carbamic acid, [(1S)-2-[(6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


yl)amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA
INDEX
NAME)

Absolute stereochemistry.




RN 253136-04-8 CAPLUS
CN Carbamic acid, [(1S)-1-methyl-2-oxo-2-[(2,3,4,5-tetrahydro-1-methyl-2-oxo-5-phenyl-1H-1-benzazepin-3-yl)amino]ethyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 253136-06-0 CAPLUS
CN L-Alaninamide, 1-[(1,1-dimethylethoxy)carbonyl]-L-prolyl-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-10-6 CAPLUS
CN 1-Piperidinecarboxylic acid, 2-[[[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-

OXO-

5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-,
1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-14-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 2-[[[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-

5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-18-4 CAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 1-[[[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-

6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-

3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-21-9 CAPLUS

CN L-Alaninamide, (4S)-1-[(1,1-dimethylethoxy)carbonyl]-4-(3-methylbutyl)-

L-prolyl-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 253136-26-4 CAPLUS

CN L-Alaninamide, (4R)-1-[(1,1-dimethylethoxy)carbonyl]-4-(3-methylbutyl)-
L-
prolyl-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 253136-31-1 CAPLUS

CN 1H-Indole-1-carboxylic acid, 2-[[[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-
5H-
dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]amino]carbonyl]-2,3-
dihydro-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-34-4 CAPLUS


CN 1H-Indole-1-carboxylic acid, 2-[[[(1S)-2-[(7S)-6,7-dihydro-5-methyl-6-
oxo-
5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-
2,3-

Absolute stereochemistry.




CN L-Alaninamide, (4R)-1-[(1,1-dimethylethoxy) carbonyl]-4-hydroxy-L-prolyl-
 N- (6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



CN 1(2H)-Quinolinecarboxylic acid, 2-[[[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



CN 1H-Indole-1-carboxylic acid, 2-[[[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-
5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]amino]carbonyl]-2,3-

dihydro-2-methyl-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-63-9 CAPLUS

CN 1H-Indole-1-carboxylic acid, 2-[[[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-

5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-2,3-

dihydro-2-methyl-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-67-3 CAPLUS

CN 1H-Indole-1-carboxylic acid, 2,3-dihydro-3,3-dimethyl-2-[[[(1S)-1-methyl-2-

oxo-2-[[[(1S)-2,3,4,5-tetrahydro-3-methyl-2-oxo-1H-3-benzazepin-1-yl]amino]ethyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA

INDEX

NAME)




RN 253136-70-8 CAPLUS

CN 1(2H)-Quinolinecarboxylic acid, 3,4-dihydro-2-[[[(1S)-1-methyl-2-oxo-2-[[[(1S)-2,3,4,5-tetrahydro-3-methyl-2-oxo-1H-3-benzazepin-1-


yl]amino]ethyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA
INDEX
NAME)

Absolute stereochemistry.




RN 253194-29-5 CAPLUS
CN 1H-Indole-1-carboxylic acid, 2-[[[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-
oxo-
5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-
oxoethyl]amino]carbonyl]octahy
dro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 253194-31-9 CAPLUS
CN 1(2H)-Quinolinecarboxylic acid, 2-[[[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-
6-
oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-
oxoethyl]amino]carbonyl]octahydro-, 1,1-dimethylethyl ester (9CI) (CA
INDEX NAME)

Absolute stereochemistry.




RN 253194-33-1 CAPLUS

CN 1(2H)-Quinolinecarboxylic acid, 2-[[[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-

5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]amino]carbonyl]octahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 35 OF 85 CAPLUS COPYRIGHT 2003 ACS
 AN 1999:425778 CAPLUS
 DN 131:73572
 TI Preparation of annelated caprolactams as inhibitors of .beta.-amyloid
 release and/or synthesis.
 IN Audia, James E.; Mabry, Thomas E.; Nissen, Jeffrey S.; Mcdaniel, Stacey
 L.
 PA Elan Pharmaceuticals, Inc., USA; Eli Lilly and Company
 SO PCT Int. Appl., 114 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9932453	A1	19990701	WO 1998-US22637	19981029
	W:				
	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,				
	DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP,				
	KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,				
	MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,				
	TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU,				
	TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,				
	FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,				
	CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2307221	AA	19990701	CA 1998-2307221	19981029
	AU 9912777	A1	19990712	AU 1999-12777	19981029
	BR 9812773	A	20001010	BR 1998-12773	19981029
	EP 1042298	A1	20001011	EP 1998-956198	19981029
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO				
	US 2002068741	A1	20020606	US 2001-915263	20010726
	US 2002052359	A1	20020502	US 2001-915480	20010727
	US 6544978	B2	20030408		
	US 2002111343	A1	20020815	US 2001-915547	20010727
	US 2002115652	A1	20020822	US 2001-915362	20010727
	US 6541466	B2	20030401		
	US 2002123486	A1	20020905	US 2001-915342	20010727
	US 2002137738	A1	20020926	US 2001-915564	20010727
	US 6559141	B2	20030506		
	US 2002151538	A1	20021017	US 2001-915379	20010727
	US 2002173504	A1	20021121	US 2001-915519	20010727
	US 2002045747	A1	20020418	US 2001-916282	20010730
	US 2002055500	A1	20020509	US 2001-916440	20010730
PRAI	US 1996-64851P	P	19961223		
	US 1997-996422	A	19971222		
	US 1998-102726	A	19980622		
	US 1996-780025	A	19961223		
	WO 1998-US22637	W	19981029		
OS	MARPAT 131:73572				
GI					



AB R1(NHCHR2CO)nNHW [W = Q1, Q2, etc.; R1 = H, blocking group; R2 = H, (substituted) alkyl, alkenyl, alkynyl, acyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocyclyl; A, B = atoms to form aryl, (substituted) cycloalkyl, cycloalkenyl, heteroaryl, heterocyclic ring;

R3 = H, (substituted) alkyl, alkenyl, alkynyl, acyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocyclyl; R4 = (substituted) alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocyclyl; m, n = 0-2], were prepd. Thus, 7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one (prepn. given) in PhMe was treated with Bu nitrite; the mixt at 0.degree. was treated with KN(SiMe3)2 followed by 1 h stirring to give 80% 7-methyl-5-oximo-5,7-dihydro-6H-dibenz[b,d]azepin-6-one. The latter was hydrogenated in EtOH over Pd/C at 35 psi to give 61% 5-amino-7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one hydrochloride. Title compds. at 10 .mu.g/mL inhibit .beta.-amyloid prodn. by .gtoreq.30%.

IT 209984-35-0P 209984-36-1P 209984-39-4P
209984-40-7P 209984-43-0P 209984-44-1P
209985-07-9P 209985-08-0P 209985-09-1P
209994-99-0P 228877-28-9P 228877-29-0P
228877-30-3P 228877-31-4P 228877-32-5P
228877-33-6P 228877-34-7P 228877-35-8P
228877-36-9P 228877-37-0P 228877-38-1P
228877-39-2P 228877-40-5P 228877-41-6P
228877-42-7P 228877-43-8P 228877-44-9P
228877-45-0P 228877-46-1P 228877-47-2P
228877-48-3P 228877-49-4P 228877-50-7P
228877-51-8P 228877-52-9P 228877-53-0P
228877-54-1P 228877-58-5P 228877-59-6P
228877-64-3P 228877-95-0P 229021-47-0P
229021-48-1P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of annelated caprolactams as inhibitors of .beta.-amyloid release and/or synthesis)

RN 209984-35-0 CAPLUS

CN Propanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209984-36-1 CAPLUS
 CN Propanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209984-39-4 CAPLUS
 CN Butanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209984-40-7 CAPLUS
 CN Butanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209984-43-0 CAPLUS
 CN Butanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3,3-dimethyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209984-44-1 CAPLUS
 CN Butanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3,3-dimethyl-, monohydrochloride, (2S)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209985-07-9 CAPLUS
 CN Butanamide, 2-amino-N-(5-hexyl-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 209985-08-0 CAPLUS

CN Butanamide, 2-amino-N-(2-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 209985-09-1 CAPLUS

CN Butanamide, 2-amino-N-(10-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 209994-99-0 CAPLUS
 CN Propanamide, 2-amino-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 228877-28-9 CAPLUS
 CN Carbamic acid, [(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 228877-29-0 CAPLUS
 CN Carbamic acid, [(1S)-1-[[[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 228877-30-3 CAPLUS
 CN Butanamide, 2-amino-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 228877-31-4 CAPLUS
 CN Carbamic acid, [(1S)-1-[[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 228877-32-5 CAPLUS
 CN Butanamide, 2-amino-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3,3-dimethyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228877-33-6 CAPLUS
 CN Carbamic acid, [(1S)-2-[(9-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-34-7 CAPLUS

CN Propanamide, 2-amino-N-(9-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-35-8 CAPLUS

CN Carbamic acid, [(1S)-2-[(10-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 228877-36-9 CAPLUS

CN Propanamide, 2-amino-N-(10-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-

dibenz[b,d]azepin-7-yl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-37-0 CAPLUS

CN Carbamic acid, [(1S)-2-[(2S)-2-amino-1-methyl-2-oxoethyl]-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-38-1 CAPLUS

CN Propanamide, 2-amino-N-(2-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-39-2 CAPLUS

CN Carbamic acid, [(1S)-2-[[5-(cyclopropylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-40-5 CAPLUS

CN Propanamide, 2-amino-N-[5-(cyclopropylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 228877-41-6 CAPLUS

CN Carbamic acid, [(1S)-2-[[6,7-dihydro-6-oxo-5-(4-phenylbutyl)-5H-

dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-42-7 CAPLUS

CN Propanamide, 2-amino-N-[6,7-dihydro-6-oxo-5-(4-phenylbutyl)-5H-dibenz[b,d]azepin-7-yl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-43-8 CAPLUS

CN Carbamic acid, [(1S)-1-[[[5-(cyclopropylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-44-9 CAPLUS

CN Butanamide, 2-amino-N-[5-(cyclopropylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-45-0 CAPLUS

CN Carbamic acid, [(1S)-1-[[[6,7-dihydro-6-oxo-5-(4-phenylbutyl)-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-46-1 CAPLUS

CN Butanamide, 2-amino-N-[6,7-dihydro-6-oxo-5-(4-phenylbutyl)-5H-dibenz[b,d]azepin-7-yl]-3-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-47-2 CAPLUS

CN Carbamic acid, [(1S)-1-[[(5-hexyl-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-48-3 CAPLUS

CN Butanamide, 2-amino-N-(5-hexyl-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-49-4 CAPLUS

CN Carbamic acid, [(1S)-1-[[[9-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-50-7 CAPLUS

CN Butanamide, 2-amino-N-(9-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 228877-51-8 CAPLUS

CN Carbamic acid, [(1S)-1-[[[10-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]carbonyl]-2-methylpropyl]-, 1,1-

dimethylethyl
ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-52-9 CAPLUS

CN Butanamide, 2-amino-N-(10-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-53-0 CAPLUS

CN Carbamic acid, [(1S)-1-[[[2-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl
ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-54-1 CAPLUS

CN Butanamide, 2-amino-N-(2-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-58-5 CAPLUS

CN Carbamic acid, [(1S)-1-methyl-2-oxo-2-[(5,6,8,9-tetrahydro-8-oxo-4H-benzo[d]pyrido[3,2,1-jk][1]benzazepin-9-yl)amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



The chemical structure shows a benz[a]pyridine core. The nitrogen atom is at position 4. At position 5, there is a carbonyl group (C=O). At position 1, there is a methylene group (CH₂) which is part of a 1-methyl-2-((S)-1-aminopropan-2-ylthio)ethyl side chain. The side chain is attached to the nitrogen at position 1. The side chain consists of a methylene group (CH₂) attached to a chiral carbon atom (C*). The chiral carbon atom is also attached to a methyl group (Me), an amino group (NH₂), and a sulfur atom (S). The sulfur atom is part of a thioether linkage to the nitrogen at position 1.


RN	228877-64-3	CAPLUS
CN	Butanamide, 2-amino-N-(9-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)	

CN1C(=O)N2C(=C(C=C2)C3=CC=C(C=C3)F)C4=CC=CC=C4N1C

HCl

RN 228877-95-0 CAPLUS
 CN Propanamide, 2-amino-N-(5,6,8,9-tetrahydro-8-oxo-4H-benzo[d]pyrido[3,2,1-jk][1]benzazepin-9-yl)-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 229021-47-0 CAPLUS
 CN Carbamic acid, [(1S)-2-[(1,2,4,5,6,7-hexahydro-2-oxo-3,7-methano-3H-3-benzazonin-1-yl)amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 229021-48-1 CAPLUS
 CN Propanamide, 2-amino-N-(1,2,4,5,6,7-hexahydro-2-oxo-3,7-methano-3H-3-benzazonin-1-yl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 209984-33-8P 209984-34-9P 209984-37-2P
209984-38-3P 209984-41-8P 209984-42-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);

RACT


(Reactant or reagent)

(prepn. of annelated caprolactams as inhibitors of .beta.-amyloid
release and/or synthesis)

RN 209984-33-8 CAPLUS

CN Carbamic acid, [(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-
dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl
ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-34-9 CAPLUS

CN Carbamic acid, [(1S)-2-[[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-
dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl
ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-37-2 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-
dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-, 1,1-
dimethylethyl
ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-38-3 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-41-8 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-42-9 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT